Crinetics Pharmaceuticals, Inc. (CRNX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Crinetics Pharmaceuticals, Inc. (CRNX) is down 24.0% since the beginning of the year. At $35 per share, CRNX is trading 39.0% below its 52-week high of $58. Investors who bought $1,000 worth of CRNX shares 5 years ago would now be looking at an investment worth $1,743.

Crinetics Pharmaceuticals, Inc. (CRNX) has returned -24.00% so far this year and 17.31% over the past 12 months.

Based on dividend-adjusted daily data since Jul 18, 2018, CRNX's average daily return is +0.11%, while the average monthly return is +1.71%. At this rate, an investment would double in approximately 3.4 years.

Historically, 53% of months were positive and 47% were negative. The best month was Sep 2023 with a return of +71.7%, while the worst month was Jan 2022 at -33.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, CRNX closed higher 49% of trading days. The best single day was Sep 11, 2023 with a return of +63.3%, while the worst single day was Jun 22, 2020 at -17.1%.

Crinetics Pharmaceuticals, Inc. has an annualized alpha of 12.51%, beta of 1.15, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since July 18, 2018.

• This stock participated in 116.61% of S&P 500 Index downside but only 98.04% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRNX ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Crinetics Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Crinetics Pharmaceuticals, Inc. was 68.70%, occurring on Mar 16, 2020. Recovery took 948 trading sessions.

The current Crinetics Pharmaceuticals, Inc. drawdown is 41.70%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Crinetics Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Crinetics Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.